Print Page     Close Window     

2018 Press Releases

Keyword Search
2018 | 2017 | 2016 | 2015 | 2014 | 2013
01/31/18Seres Therapeutics Announces Appointment of Eric D. Shaff to Additional Role of Chief Operating Officer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 31, 2018-- Seres Therapeutics, Inc., (NASDAQ:MCRB) today announced the appointment of Eric D. Shaff to the additional role of Chief Operating Officer. Mr. Shaff has been Executive Vice President and Chief Financial Officer since joining the Company in November 2014, and he will continue to retain both positions. Roger J. Pomerantz, M.D., President, CEO and Chairman of Seres, commented: “Eric h... 
 Printer Friendly Version
01/04/18Seres Therapeutics Reports SER-287 Phase 1b Microbiome Analyses that Provide Mechanistic Support for Clinical Efficacy in Ulcerative Colitis
- Microbiome analyses demonstrate engraftment of SER-287-derived bacteria; microbiome compositional changes correlate with clinical remission - - SER-287 engraftment maintained four weeks after completion of dosing - - Company to discuss proposed SER-287 development plan with FDA and intends to initiate next clinical trial in mid-2018 - - FDA granted SER-287 Orphan Drug designation for treatment of pediatric UC patie... 
 Printer Friendly Version
01/04/18Seres Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 4, 2018-- Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced that it will present at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Thursday, January 11 at 8:30 a.m. PT. A live audio webcast of the presentation and breakout question and answer session will be available under the “Investors and Media” section of Seres’ website. A replay of the presentation will become av... 
 Printer Friendly Version

© Seres Therapeutics. All Rights Reserved.